Quantum BioPharma Completes 180-Day Toxicity Dosing for Lead MS Drug Lucid-MS

An update from Quantum Biopharma ( (TSE:QNTM) ) is now available.

On December 23, 2025, Quantum BioPharma announced it has completed oral dosing in its 180-day repeated-dose oral toxicity and toxicokinetic studies for its lead multiple sclerosis candidate Lucid-21-302 (Lucid-MS), a key milestone in the program’s non-clinical development. The completion of these chronic toxicity studies is described by management as a critical step toward supporting an Investigational New Drug application with the U.S. Food and Drug Administration and informing the design of a planned Phase 2 clinical trial in people with multiple sclerosis, potentially advancing a first-in-class therapy aimed at preventing disease progression and inhibiting demyelination, and marking tangible progress that could enhance the company’s positioning in the neurodegenerative disease segment.

More about Quantum Biopharma

Quantum BioPharma Ltd. is a Toronto-based biopharmaceutical company focused on developing innovative therapeutics for challenging neurodegenerative and metabolic disorders and alcohol misuse disorders, with drug candidates at various stages of development. Through its subsidiary Lucid Psycheceuticals, the company is advancing its lead compound Lucid-21-302 (Lucid-MS), a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation in preclinical multiple sclerosis models. Quantum also retains an equity stake and royalty interest in Unbuzzd Wellness Inc., which markets an over-the-counter product derived from Quantum’s unbuzzd formulation, and it holds a portfolio of property-backed strategic investments via its FSD Strategic Investments unit.

Average Trading Volume: 5,005

Technical Sentiment Signal: Sell

Current Market Cap: C$47.03M

See more insights into QNTM stock on TipRanks’ Stock Analysis page.